SCYNEXIS, Inc. is a pharmaceutical company committed to the discovery, development and commercialization of anti-infectives to address unmet therapeutic needs. The Company is developing its lead product candidate, SCY-078, as an oral and intravenous (IV) drug for the treatment of serious and life-threatening invasive fungal infections in humans. SCY-078 represents a new chemical class of drugs designed to block an established target in infectious fungi. The Company is developing both an IV and oral formulation of SCY-078. SCY-078 is a potent inhibitor of the synthesis of the fungal cell wall polymer glucan, an essential component of Candida and Aspergillus species. The compound is derived, by chemical modification, from a natural product that shows anti-fungal activity against Candida and Aspergillus through inhibition of glucan synthesis, like the echinocandin class.
Address
3501-C TRICENTER BLVD
DURHAM, NC 27713
United States
